The CCHFV patient sample Biobank has played a crucial role in generating datasets on adaptive immune and omic responses to CCHFV, offering insights that could significantly contribute to the development of life-saving vaccines and therapeutics. Several compelling research reports are in the pipeline for publication.
Moreover, our collaborative efforts have facilitated the establishment of fruitful relationships with CCHF-endemic countries, including not only Turkey and Tajikistan but also South Africa and India. Interactions with leading Biotech companies, such as Pfizer, Astra, and Biontech, have been initiated, positioning us as a valuable resource in the ongoing fight against CCHF.
The CCHFVaccine programme established the first sheep animal model for CCHFV and subsequently tested vaccine candidates using this model. In parallel, the programme has developed tools, methodologies, and scalable vaccination strategies for domestic animals in endemic and neighbouring regions. By targeting the animal reservoir, these efforts have the potential to markedly reduce viral circulation and strengthen disease control in Europe and globally. This progress provides strong momentum and tangible hope that effective vaccination strategies against CCHFV are within reach.
The project has successfully generated multiple human vaccine candidates using two complementary and advanced platforms: DNA-based and mRNA-based vaccines, positioning the field for rapid clinical translation and improved preparedness against future outbreaks. Furthermore, a Phase I clinical trial to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 against Crimean Congo Hemorrhagic Fever was conducted.
In addition to the activities outlined above, training workshops and exchange programmes have empowered scientists with advanced skills, harmonised SOPs, and hands-on experience, enabling rapid implementation of cutting-edge techniques across participating laboratories. This strong commitment to capacity building, combined with the multidisciplinary approach at the core of CCHFVaccine, is firmly grounded in a public health–driven rationale and ensures that scientific advances translate into sustainable impact, preparedness, and long-term benefit.
A defining strength of CCHFVaccine has been its integrative and collaborative approach. By building on, aligning with, and complementing other nationally and internationally funded projects—particularly European Commission–supported initiatives—the programme created strong synergies, avoided duplication, and accelerated progress toward shared public health goals. This coordinated framework has maximized impact, strengthened preparedness, and ensured that CCHFVaccine outcomes are embedded within the broader European and global response to emerging viral threats.
